Lido Advisors
CRSP icon

Lido Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Lido Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,816
Closed -$260K – 1431
2024
Q1 		$260K Buy
+3,816
New +$273K ﹤0.01% 1155

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Lido Advisors's CRSP Position: Q2 2024 in Review

Lido Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 3,816 shares — an estimated $260K sold.

Lido Advisors first reported a position in CRSP in Q1 2024 and held it in 1 quarter. The position peaked at $260K in Q1 2024. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

  • Lido Advisors reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lido Advisors sold 3,816 CRISPR Therapeutics shares in Q2 2024, an estimated $260K.
  • Lido Advisors first reported a position in CRISPR Therapeutics in Q1 2024 and held it in 1 quarter.
  • Lido Advisors's CRISPR Therapeutics position peaked at $260K in Q1 2024.
  • 449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Lido Advisors's 13F filing for Q2 2024, filed 15 Aug 2024.